Claudia Vergelli Selected Research

Type 5 Cyclic Nucleotide Phosphodiesterases

8/2006

Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Claudia Vergelli Research Topics

Disease

3	Inflammation (Inflammations) 01/2020 - 08/2011
2	Rheumatoid Arthritis 10/2021 - 01/2020
2	Pain (Aches) 12/2017 - 03/2009
1	Neoplasms (Cancer) 10/2021
1	Lung Injury 01/2020
1	Nervous System Diseases (Neurological Disorders) 12/2017
1	Neuralgia (Stump Neuralgia) 01/2017
1	Arthritis (Polyarthritis) 01/2016
1	Lung Diseases (Lung Disease) 08/2013
1	Erectile Dysfunction 08/2006
1	Chronic Obstructive Pulmonary Disease (COPD) 04/2002
1	Asthma (Bronchial Asthma) 04/2002

Drug/Important Bio-Agent (IBA)

4	Formyl Peptide Receptors (Formyl Peptide Receptor)IBA 10/2021 - 06/2013
3	Leukocyte Elastase (Neutrophil Elastase)IBA 01/2020 - 08/2011
1	BenzodiazepinesIBA 12/2017
1	LigandsIBA 12/2017
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2017
1	Secretory Proteinase Inhibitory ProteinsIBA 01/2016
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 03/2009
1	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 08/2006
1	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 04/2002